<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35178615</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>28</Day></DateCompleted><DateRevised><Year>2022</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1435-1463</ISSN><JournalIssue CitedMedium="Internet"><Volume>129</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Journal of neural transmission (Vienna, Austria : 1996)</Title><ISOAbbreviation>J Neural Transm (Vienna)</ISOAbbreviation></Journal><ArticleTitle>Serum NfL and CHI3L1 for ALS and parkinsonian disorders in the process of diagnosis.</ArticleTitle><Pagination><StartPage>301</StartPage><EndPage>309</EndPage><MedlinePgn>301-309</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00702-022-02470-z</ELocationID><Abstract><AbstractText>Serum neurofilament light chain (NfL) and chitinase 3-like 1 (CHI3L1, also called YKL-40) concentrations are attractive candidate biomarkers for neurodegenerative disorders, which include amyotrophic lateral sclerosis (ALS) and parkinsonian disorders. We aimed to assess the diagnostic power of serum NfL and CHI3L1 concentrations with regard to the early diagnosis of ALS and Parkinson's disease (PD). We studied 157 individuals, which included 41 healthy controls, 8 patients with ALS mimics, 18 patients initially diagnosed with ALS (ID-ALS), 32 patients late-diagnosed with ALS (LD-ALS), 29 patients with PD, 12 patients with PD mimics, and 17 patients initially diagnosed with atypical parkinsonian disorders (ID-APDs) at the initial stage of diagnosis. Electrochemiluminescence was used to measure the concentrations of serum NfL and CHI3L1, the diagnostic performance of which was assessed using the area under the receiver operating curves (AUCs). The AUCs of serum NfL were 0.90 for discriminating ALS mimics from LD-ALS at the initial stage of diagnosis and 0.89 for discriminating ALS mimics from ALS (LD/ID-ALS). The AUCs of serum NfL were 0.76 for discriminating PD from PD mimics at the initial stage of diagnosis, and 0.80 for discriminating PD from APD. No significant difference existed in serum CHI3L1 concentrations between individuals with suspected ALS or parkinsonism (p&#x2009;=&#x2009;0.14, and p&#x2009;=&#x2009;0.44, respectively). Serum NfL had excellent and almost good diagnostic performances for patients with ALS and PD, respectively, at the initial stage of diagnosis, whereas no significant difference existed in serum CHI3L1 between any groups.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Haji</LastName><ForeName>Shotaro</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sako</LastName><ForeName>Wataru</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0003-2009-2486</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan. dwsako@yahoo.co.jp.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Faculty of Medicine, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan. dwsako@yahoo.co.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murakami</LastName><ForeName>Nagahisa</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Shinko Hospital, Kobe, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Osaki</LastName><ForeName>Yusuke</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Izumi</LastName><ForeName>Yuishin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Austria</Country><MedlineTA>J Neural Transm (Vienna)</MedlineTA><NlmUniqueID>9702341</NlmUniqueID><ISSNLinking>0300-9564</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C084533">CHI3L1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000071451">Chitinase-3-Like Protein 1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071451" MajorTopicYN="N">Chitinase-3-Like Protein 1</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020734" MajorTopicYN="Y">Parkinsonian Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">CHI3L1</Keyword><Keyword MajorTopicYN="N">Multiple system atrophy</Keyword><Keyword MajorTopicYN="N">NfL</Keyword><Keyword MajorTopicYN="N">Parkinson&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">Progressive supranuclear palsy</Keyword><Keyword MajorTopicYN="N">YKL-40</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>18</Day><Hour>5</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35178615</ArticleId><ArticleId IdType="doi">10.1007/s00702-022-02470-z</ArticleId><ArticleId IdType="pii">10.1007/s00702-022-02470-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alagaratnam J, von Widekind S, De Francesco D, Underwood J, Edison P, Winston A, Zetterberg H, Fidler S (2021) Correlation between CSF and blood neurofilament light chain protein: a systematic review and meta-analysis. BMJ Neurol Open 3(1):e000143. https://doi.org/10.1136/bmjno-2021-000143</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjno-2021-000143</ArticleId><ArticleId IdType="pubmed">34223154</ArticleId><ArticleId IdType="pmc">8211066</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcolea D, Vilaplana E, Su&#xe1;rez-Calvet M, Ill&#xe1;n-Gala I, Blesa R, Clarim&#xf3;n J, Llad&#xf3; A, S&#xe1;nchez-Valle R, Molinuevo JL, Garc&#xed;a-Ribas G, Compta Y, Mart&#xed; MJ, Pi&#xf1;ol-Ripoll G, Amer-Ferrer G, Noguera A, Garc&#xed;a-Mart&#xed;n A, Fortea J, Lle&#xf3; A (2017) CSF sAPP&#x3b2;, YKL-40, and neurofilament light in frontotemporal lobar degeneration. Neurology 89(2):178&#x2013;188. https://doi.org/10.1212/wnl.0000000000004088</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.0000000000004088</ArticleId><ArticleId IdType="pubmed">28592456</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B, Boxer AL, Dickson DW, Grossman M, Hallett M, Josephs KA, Kertesz A, Lee SE, Miller BL, Reich SG, Riley DE, Tolosa E, Troster AI, Vidailhet M, Weiner WJ (2013) Criteria for the diagnosis of corticobasal degeneration. Neurology 80(5):496&#x2013;503. https://doi.org/10.1212/WNL.0b013e31827f0fd1</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e31827f0fd1</ArticleId><ArticleId IdType="pubmed">23359374</ArticleId><ArticleId IdType="pmc">3590050</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J, Andersen PM, Lombardi V, Malaspina A (2018) Neurofilament light: a candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann Neurol 84(1):130&#x2013;139. https://doi.org/10.1002/ana.25276</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25276</ArticleId><ArticleId IdType="pubmed">30014505</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J, Lombardi V, Jeromin A, Bowser R, Andersen PM, Malaspina A (2019) Neurofilaments in pre-symptomatic ALS and the impact of genotype. Amyotroph Lateral Scler Front Degener 20(7&#x2013;8):538&#x2013;548. https://doi.org/10.1080/21678421.2019.1646769</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1646769</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, Nakanishi A (1999) The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 169(1&#x2013;2):13&#x2013;21</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(99)00210-5</ArticleId><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa J, Swash M, de Carvalho M (2012) Awaji criteria for the diagnosis of amyotrophic lateral sclerosis:a systematic review. Arch Neurol 69(11):1410&#x2013;1416. https://doi.org/10.1001/archneurol.2012.254</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneurol.2012.254</ArticleId><ArticleId IdType="pubmed">22892641</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Rosa M, Distefano G, Zorena K, Malaguarnera L (2016) Chitinases and immunity: ancestral molecules with new functions. Immunobiology 221(3):399&#x2013;411. https://doi.org/10.1016/j.imbio.2015.11.014</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imbio.2015.11.014</ArticleId><ArticleId IdType="pubmed">26686909</ArticleId></ArticleIdList></Reference><Reference><Citation>Feneberg E, Oeckl P, Steinacker P, Verde F, Barro C, Van Damme P, Gray E, Grosskreutz J, Jardel C, Kuhle J, Koerner S, Lamari F, Amador MDM, Mayer B, Morelli C, Muckova P, Petri S, Poesen K, Raaphorst J, Salachas F, Silani V, Stubendorff B, Turner MR, Verbeek MM, Weishaupt JH, Weydt P, Ludolph AC, Otto M (2018) Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology 90(1):e22&#x2013;e30. https://doi.org/10.1212/wnl.0000000000004761</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.0000000000004761</ArticleId><ArticleId IdType="pubmed">29212830</ArticleId></ArticleIdList></Reference><Reference><Citation>Forsaa EB, Larsen JP, Wentzel-Larsen T, Alves G (2010) What predicts mortality in Parkinson disease?: a prospective population-based long-term study. Neurology 75(14):1270&#x2013;1276. https://doi.org/10.1212/WNL.0b013e3181f61311</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181f61311</ArticleId><ArticleId IdType="pubmed">20921512</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H (2019) Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry 90(8):870&#x2013;881. https://doi.org/10.1136/jnnp-2018-320106</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-320106</ArticleId><ArticleId IdType="pubmed">30967444</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaiani A, Martinelli I, Bello L, Querin G, Puthenparampil M, Ruggero S, Toffanin E, Cagnin A, Briani C, Pegoraro E, Sorar&#xf9; G (2017) Diagnostic and prognostic biomarkers in amyotrophic lateral sclerosis: neurofilament light chain levels in definite subtypes of disease. JAMA Neurol 74(5):525&#x2013;532. https://doi.org/10.1001/jamaneurol.2016.5398</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2016.5398</ArticleId><ArticleId IdType="pubmed">28264096</ArticleId><ArticleId IdType="pmc">5822207</ArticleId></ArticleIdList></Reference><Reference><Citation>Gille B, De Schaepdryver M, Dedeene L, Goossens J, Claeys KG, Van Den Bosch L, Tournoy J, Van Damme P, Poesen K (2019) Inflammatory markers in cerebrospinal fluid: independent prognostic biomarkers in amyotrophic lateral sclerosis? J Neurol Neurosurg Psychiatry 90(12):1338&#x2013;1346. https://doi.org/10.1136/jnnp-2018-319586</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-319586</ArticleId><ArticleId IdType="pubmed">31175169</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, Wood NW, Colosimo C, Durr A, Fowler CJ, Kaufmann H, Klockgether T, Lees A, Poewe W, Quinn N, Revesz T, Robertson D, Sandroni P, Seppi K, Vidailhet M (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71(9):670&#x2013;676. https://doi.org/10.1212/01.wnl.0000324625.00404.15</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000324625.00404.15</ArticleId><ArticleId IdType="pubmed">18725592</ArticleId><ArticleId IdType="pmc">2676993</ArticleId></ArticleIdList></Reference><Reference><Citation>Gray E, Thompson AG, Wuu J, Pelt J, Talbot K, Benatar M, Turner MR (2020) CSF chitinases before and after symptom onset in amyotrophic lateral sclerosis. Ann Clin Transl Neurol. https://doi.org/10.1002/acn3.51114</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51114</ArticleId><ArticleId IdType="pubmed">32666680</ArticleId><ArticleId IdType="pmc">7448184</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall S, Janelidze S, Surova Y, Widner H, Zetterberg H, Hansson O (2018) Cerebrospinal fluid concentrations of inflammatory markers in Parkinson&#x2019;s disease and atypical parkinsonian disorders. Sci Rep 8(1):13276. https://doi.org/10.1038/s41598-018-31517-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-31517-z</ArticleId><ArticleId IdType="pubmed">30185816</ArticleId><ArticleId IdType="pmc">6125576</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansson O, Janelidze S, Hall S, Magdalinou N, Lees AJ, Andreasson U, Norgren N, Linder J, Forsgren L, Constantinescu R, Zetterberg H, Blennow K (2017) Blood-based NfL: a biomarker for differential diagnosis of parkinsonian disorder. Neurology 88(10):930&#x2013;937. https://doi.org/10.1212/wnl.0000000000003680</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.0000000000003680</ArticleId><ArticleId IdType="pubmed">28179466</ArticleId><ArticleId IdType="pmc">5333515</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoglinger GU, Respondek G, Stamelou M, Kurz C, Josephs KA, Lang AE, Mollenhauer B, Muller U, Nilsson C, Whitwell JL, Arzberger T, Englund E, Gelpi E, Giese A, Irwin DJ, Meissner WG, Pantelyat A, Rajput A, van Swieten JC, Troakes C, Antonini A, Bhatia KP, Bordelon Y, Compta Y, Corvol JC, Colosimo C, Dickson DW, Dodel R, Ferguson L, Grossman M, Kassubek J, Krismer F, Levin J, Lorenzl S, Morris HR, Nestor P, Oertel WH, Poewe W, Rabinovici G, Rowe JB, Schellenberg GD, Seppi K, van Eimeren T, Wenning GK, Boxer AL, Golbe LI, Litvan I (2017) Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord 32(6):853&#x2013;864. https://doi.org/10.1002/mds.26987</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.26987</ArticleId><ArticleId IdType="pubmed">28467028</ArticleId><ArticleId IdType="pmc">5516529</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson&#x2019;s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55(3):181&#x2013;184. https://doi.org/10.1136/jnnp.55.3.181</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.55.3.181</ArticleId><ArticleId IdType="pubmed">1564476</ArticleId><ArticleId IdType="pmc">1014720</ArticleId></ArticleIdList></Reference><Reference><Citation>Ill&#xe1;n-Gala I, Alcolea D, Montal V, Dols-Icardo O, Mu&#xf1;oz L, de Luna N, Tur&#xf3;n-Sans J, Cort&#xe9;s-Vicente E, S&#xe1;nchez-Saudin&#xf3;s MB, Subirana A, Sala I, Blesa R, Clarim&#xf3;n J, Fortea J, Rojas-Garc&#xed;a R, Lle&#xf3; A (2018) CSF sAPP&#x3b2;, YKL-40, and NfL along the ALS-FTD spectrum. Neurology 91(17):e1619&#x2013;e1628. https://doi.org/10.1212/wnl.0000000000006383</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.0000000000006383</ArticleId><ArticleId IdType="pubmed">30291183</ArticleId></ArticleIdList></Reference><Reference><Citation>Kempster PA, O&#x2019;Sullivan SS, Holton JL, Revesz T, Lees AJ (2010) Relationships between age and late progression of Parkinson&#x2019;s disease: a clinico-pathological study. Brain 133(Pt 6):1755&#x2013;1762. https://doi.org/10.1093/brain/awq059</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awq059</ArticleId><ArticleId IdType="pubmed">20371510</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalil M, Teunissen CE, Otto M, Piehl F, Sormani MP, Gattringer T, Barro C, Kappos L, Comabella M, Fazekas F, Petzold A, Blennow K, Zetterberg H, Kuhle J (2018) Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 14(10):577&#x2013;589. https://doi.org/10.1038/s41582-018-0058-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41582-018-0058-z</ArticleId><ArticleId IdType="pubmed">30171200</ArticleId></ArticleIdList></Reference><Reference><Citation>Kouli A, Horne CB, Williams-Gray CH (2019) Toll-like receptors and their therapeutic potential in Parkinson&#x2019;s disease and &#x3b1;-synucleinopathies. Brain Behav Immun 81:41&#x2013;51. https://doi.org/10.1016/j.bbi.2019.06.042</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2019.06.042</ArticleId><ArticleId IdType="pubmed">31271873</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhle J, Barro C, Andreasson U, Derfuss T, Lindberg R, Sandelius &#xc5;, Liman V, Norgren N, Blennow K, Zetterberg H (2016) Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med 54(10):1655&#x2013;1661. https://doi.org/10.1515/cclm-2015-1195</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/cclm-2015-1195</ArticleId><ArticleId IdType="pubmed">27071153</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin CH, Li CH, Yang KC, Lin FJ, Wu CC, Chieh JJ, Chiu MJ (2019) Blood NfL: a biomarker for disease severity and progression in Parkinson disease. Neurology 93(11):e1104&#x2013;e1111. https://doi.org/10.1212/wnl.0000000000008088</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.0000000000008088</ArticleId><ArticleId IdType="pubmed">31420461</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu CH, Macdonald-Wallis C, Gray E, Pearce N, Petzold A, Norgren N, Giovannoni G, Fratta P, Sidle K, Fish M, Orrell R, Howard R, Talbot K, Greensmith L, Kuhle J, Turner MR, Malaspina A (2015) Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology 84(22):2247&#x2013;2257. https://doi.org/10.1212/wnl.0000000000001642</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.0000000000001642</ArticleId><ArticleId IdType="pubmed">25934855</ArticleId><ArticleId IdType="pmc">4456658</ArticleId></ArticleIdList></Reference><Reference><Citation>Magdalinou N, Lees AJ, Zetterberg H (2014) Cerebrospinal fluid biomarkers in parkinsonian conditions: an update and future directions. J Neurol Neurosurg Psychiatry 85(10):1065&#x2013;1075. https://doi.org/10.1136/jnnp-2013-307539</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2013-307539</ArticleId><ArticleId IdType="pubmed">24691581</ArticleId></ArticleIdList></Reference><Reference><Citation>Marques TM, van Rumund A, Oeckl P, Kuiperij HB, Esselink RAJ, Bloem BR, Otto M, Verbeek MM (2019) Serum NFL discriminates Parkinson disease from atypical parkinsonisms. Neurology 92(13):e1479&#x2013;e1486. https://doi.org/10.1212/wnl.0000000000007179</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.0000000000007179</ArticleId><ArticleId IdType="pubmed">30814322</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng ASL, Tan YJ, Yong ACW, Saffari SE, Lu Z, Ng EY, Ng SYE, Chia NSY, Choi X, Heng D, Neo S, Xu Z, Keong NCH, Tay KY, Au WL, Tan LCS, Tan EK (2020) Utility of plasma Neurofilament light as a diagnostic and prognostic biomarker of the postural instability gait disorder motor subtype in early Parkinson&#x2019;s disease. Mol Neurodegener 15(1):33. https://doi.org/10.1186/s13024-020-00385-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-020-00385-5</ArticleId><ArticleId IdType="pubmed">32503574</ArticleId><ArticleId IdType="pmc">7275464</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson B, Constantinescu R, Holmberg B, Andreasen N, Blennow K, Zetterberg H (2013) The glial marker YKL-40 is decreased in synucleinopathies. Mov Disord 28(13):1882&#x2013;1885. https://doi.org/10.1002/mds.25589</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.25589</ArticleId><ArticleId IdType="pubmed">23847144</ArticleId></ArticleIdList></Reference><Reference><Citation>Rissin DM, Kan CW, Campbell TG, Howes SC, Fournier DR, Song L, Piech T, Patel PP, Chang L, Rivnak AJ, Ferrell EP, Randall JD, Provuncher GK, Walt DR, Duffy DC (2010) Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations. Nat Biotechnol 28(6):595&#x2013;599. https://doi.org/10.1038/nbt.1641</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nbt.1641</ArticleId><ArticleId IdType="pubmed">20495550</ArticleId><ArticleId IdType="pmc">2919230</ArticleId></ArticleIdList></Reference><Reference><Citation>Sako W, Murakami N, Izumi Y, Kaji R (2015) Neurofilament light chain level in cerebrospinal fluid can differentiate Parkinson&#x2019;s disease from atypical parkinsonism: evidence from a meta-analysis. J Neurol Sci 352(1&#x2013;2):84&#x2013;87. https://doi.org/10.1016/j.jns.2015.03.041</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2015.03.041</ArticleId><ArticleId IdType="pubmed">25868897</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanfilippo C, Longo A, Lazzara F, Cambria D, Distefano G, Palumbo M, Cantarella A, Malaguarnera L, Di Rosa M (2017) CHI3L1 and CHI3L2 overexpression in motor cortex and spinal cord of sALS patients. Mol Cell Neurosci 85:162&#x2013;169. https://doi.org/10.1016/j.mcn.2017.10.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2017.10.001</ArticleId><ArticleId IdType="pubmed">28989002</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson AG, Gray E, Th&#xe9;z&#xe9;nas ML, Charles PD, Evetts S, Hu MT, Talbot K, Fischer R, Kessler BM, Turner MR (2018) Cerebrospinal fluid macrophage biomarkers in amyotrophic lateral sclerosis. Ann Neurol 83(2):258&#x2013;268. https://doi.org/10.1002/ana.25143</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.25143</ArticleId><ArticleId IdType="pubmed">29331073</ArticleId></ArticleIdList></Reference><Reference><Citation>Venezia S, Kaufmann WA, Wenning GK, Stefanova N (2021) Toll-like receptor 4 deficiency facilitates &#x3b1;-synuclein propagation and neurodegeneration in a mouse model of prodromal Parkinson&#x2019;s disease. Parkinsonism Relat Disord 91:59&#x2013;65. https://doi.org/10.1016/j.parkreldis.2021.09.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2021.09.007</ArticleId><ArticleId IdType="pubmed">34530328</ArticleId></ArticleIdList></Reference><Reference><Citation>Verde F, Steinacker P, Weishaupt JH, Kassubek J, Oeckl P, Halbgebauer S, Tumani H, von Arnim CAF, Dorst J, Feneberg E, Mayer B, M&#xfc;ller HP, Gorges M, Rosenbohm A, Volk AE, Silani V, Ludolph AC, Otto M (2019) Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 90(2):157&#x2013;164. https://doi.org/10.1136/jnnp-2018-318704</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2018-318704</ArticleId><ArticleId IdType="pubmed">30309882</ArticleId></ArticleIdList></Reference><Reference><Citation>Vu L, An J, Kovalik T, Gendron T, Petrucelli L, Bowser R (2020) Cross-sectional and longitudinal measures of chitinase proteins in amyotrophic lateral sclerosis and expression of CHI3L1 in activated astrocytes. J Neurol Neurosurg Psychiatry 91(4):350&#x2013;358. https://doi.org/10.1136/jnnp-2019-321916</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2019-321916</ArticleId><ArticleId IdType="pubmed">31937582</ArticleId></ArticleIdList></Reference><Reference><Citation>Wennstr&#xf6;m M, Surova Y, Hall S, Nilsson C, Minthon L, Hansson O, Nielsen HM (2015) The inflammatory marker YKL-40 is elevated in cerebrospinal fluid from patients with Alzheimer&#x2019;s but not Parkinson&#x2019;s disease or Dementia with Lewy bodies. PLoS ONE 10(8):e0135458. https://doi.org/10.1371/journal.pone.0135458</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0135458</ArticleId><ArticleId IdType="pubmed">26270969</ArticleId><ArticleId IdType="pmc">4536228</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson DH, Rissin DM, Kan CW, Fournier DR, Piech T, Campbell TG, Meyer RE, Fishburn MW, Cabrera C, Patel PP, Frew E, Chen Y, Chang L, Ferrell EP, von Einem V, McGuigan W, Reinhardt M, Sayer H, Vielsack C, Duffy DC (2016) The Simoa HD-1 analyzer: a novel fully automated digital immunoassay analyzer with single-molecule sensitivity and multiplexing. J Lab Autom 21(4):533&#x2013;547. https://doi.org/10.1177/2211068215589580</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2211068215589580</ArticleId><ArticleId IdType="pubmed">26077162</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>